An observational study in Premature Birth, sponsored by University of Oxford. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 3 Years to 9 Years. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by University of Oxford · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Premature Birth by University of Oxford — 3 open to participants now, 4 under way, none of them phase 3. Premature Birth · University of Oxford.
Among the 11 studies in Premature Birth by University of Oxford, this one is the only one that started in 2019, is one of 9 observational ones, and was the 8th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →3 of the 11 studies in Premature Birth by University of Oxford are open now, in 1 country. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages up to 37 wk
University of Oxford · Sites in United Kingdom
Ages up to 42 wk
By country, each count listing its studies:
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 3 Years to 9 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2019.
This study's planned enrollment of 200 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 1,504 across the 2 interventional studies, 200 across the 9 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Premature Birth by University of Oxford, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the CHAPTER study is to help understand how complications during pregnancy, such as preterm birth, affect how childrens' hearts and blood vessels develop.
Young adults born preterm (less than 37 weeks gestation) have alterations in the structure and function of the heart, with similar changes observed in preterm infants in the first three months of life. It is unknown whether these early changes in the heart seen in the first few months of life are relevant to long-term changes in heart structure and function. Heart changes have also not been well studied in children born preterm. To investigate this, the study will follow up children from the EPOCH study and will perform two study visits for each child (n=100 preterm and n=100 term) that will use echocardiography and cardiovascular magnetic resonance. Individuals in the EPOCH study had echocardiography measures done at birth and three months postnatal age. It will therefore be possible to do longitudinal echocardiography measures from birth up to ages 12 years to determine whether postnatal heart changes in preterm infants track into childhood. Cardiovascular magnetic resonance will allow for the determination of whether these early heart changes influence heart pump function. Finally, by measuring lung function, blood vessel structure and function, and blood pressure, it will be possible to determine how heart changes relate to other components of the cardiovascular system. This data will be used to confirm the relevance of early heart remodelling in preterm-born offspring over time and provide more comprehensive heart phenotyping for preterm-born children. Together, this information can be used to design future intervention strategies in preterm-born individuals to reduce cardiovascular risk in this growing subgroup of the population.
Children aged 3--12 years old born preterm (less than 37 weeks gestation) or term (37--42 weeks gestation) delivered at or admitted to the Oxford University Hospitals NHS Foundation Trust who took part in the EPOCH study. Recruitment also includes both siblings and friends of those who took part in the original EPOCH study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For exclusion of MRI component only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cardiac left ventricular mass
Echocardiography assessment of left ventricular mass indexed to body surface area (in g and g/m\^2)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac right ventricular mass
Echocardiography assessment of right ventricular mass indexed to body surface area (in g and g/m\^2)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac left ventricular end-diastolic volume
Echocardiography assessment of cardiac left ventricular end-diastolic volume indexed to body surface area (in ml and ml/m\^2)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac right ventricular end-diastolic volume
Echocardiography assessment of cardiac right ventricular end-diastolic volume indexed to body surface area (in ml and ml/m\^2)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac left ventricular systolic function
Echocardiography assessment of left ventricular systolic function: left ventricular ejection fraction (in %)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac right ventricular systolic function
Echocardiography assessment of right ventricular systolic function: tricuspid annular plane systolic excursion (in cm)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac left ventricular diastolic function
Echocardiography assessment of right ventricular (RV) diastolic function: RV Doppler early/late diastolic tricuspid inflow velocity ratio (E/A)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Cardiac right ventricular diastolic function
Echocardiography assessment of left ventricular (LV) diastolic function: LV Doppler early/late diastolic mitral inflow
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Morphology of the left ventricles
MRI assessment of the left ventricles morphology using cardiac statistical atlas and principal component analysis
Time frame: 6-9 years of age
Morphology of the right ventricles
MRI assessment of the right ventricles morphology using cardiac statistical atlas and principal component analysis
Time frame: 6-9 years of age
Cardiac flow dynamics of the left ventricle
MRI assessment of direct flow, delayed ejection flow, retained inflow, residual volume kinetic energy flow components at end diastole (measured at end diastole in mJ and overall % contribution)
Time frame: 6-9 years of age
Systolic blood pressure measurement
Resting brachial blood pressure measurement (in mmHg)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Diastolic blood pressure measurement
Resting brachial blood pressure measurement (in mmHg)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Mean arterial pressure
The average arterial pressure from resting brachial blood pressure measurement (in mmHg)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Retinal arteriolar structure
Central retinal arteriolar equivalent (CRAE in μm) measured using retinal imaging
Time frame: 6-9 years of age
Retinal venular structure
Central retinal venular equivalent (CRVE in μm) measured using retinal imaging
Time frame: 6-9 years of age
Retinal arteriolar-to-venular diameter ratio (AVR)
The ratio of average retinal arteriolar diameter (CRAE in μm) and average retinal venous diameter (CRVE in μm) measured using retinal imaging
Time frame: 6-9 years of age
Lung function
The forced expiratory volume in one second (FEV1 in L), forced vital capacity (FVC in L), and the ratio of FEV1 to FVC (FEV1/FVC) measured using spirometry
Time frame: 6-9 years of age
Objective measure of physical activity
The amount of moderate to vigorous physical activity (in h/week) and vigorous physical activity (in h/week) measured using wrist worn accelerometer
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Body weight
Body weight measured in kg
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Body height
Body weight measured in m
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Body mass index
Body weight divided by the square of height (in kg/m2)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Mid-arm circumference
Mid-arm circumference measured in cm
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Waist-to-hip ratio
The ratio of waist circumference (in cm) to hip circumference (in cm)
Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age
Tube formation capacity in endothelial colony forming cells (ECFCs)
The number of closed tubes formed/1.5x10\^4 cells
Time frame: 6-9 years of age
Endothelial colony forming cells (ECFC) branches formed
The number of branches formed/1.5x10\^4 cells
Time frame: 6-9 years of age
Endothelial colony forming cells (ECFC) colony formation
Days for ECFC colony formation, measured in days
Time frame: 6-9 years of age
Endothelial colony forming cells (ECFC) proliferation rate
ECFC proliferation rate, measured as a percentage
Time frame: 6-9 years of age
Subcortical brain volume of hippocampus
Subcortical brain volume of hippocampus (in mm3) assessed on T1-weighted sequence of brain MRI
Time frame: 6-9 years of age
Subcortical brain volume of thalamus
Subcortical brain volume of thalamus (in mm3) assessed on T1-weighted sequence of brain MRI
Time frame: 6-9 years of age
White matter hyperintensities count
The number of white matter hyperintensities on T2-weighted sequence of brain MRI
Time frame: 6-9 years of age
White matter hyperintensities volume
Total volume of white matter hyperintensities (in mm3) assessed on T2-weighted sequence of brain MRI
Time frame: 6-9 years of age
Cerebral vessel lumen diameter
Cerebral vessel lumen diameter (in μm) assessed on the time-of-flight sequence of brain MRI
Time frame: 6-9 years of age
Cerebral vessel density
Cerebral vessel density (in mm3) assessed on the time-of-flight sequence of brain MRI
Time frame: 6-9 years of age
Cerebral vessel tortuosity
The ratio of cerebral vessel tortuosity assessed on the time-of-flight sequence of brain MRI
Time frame: 6-9 years of age
Whole brain grey matter perfusion or cerebral blood flow (CBF)
Whole brain grey matter perfusion/CBF (in ml/100g/min) assessed on arterial spin labelling of brain MRI
Time frame: 6-9 years of age
Arterial cerebral blood volume fraction
Arterial cerebral blood volume fraction (in %) assessed on arterial spin labelling of brain MRI
Time frame: 6-9 years of age
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2019 (actual). Primary completion is estimated for May 2023, 50 months after the start.
Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 50 months is above that.
Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.